Co-Diagnostics Inc. Common Stock (CODX)
Stock · NASDAQ · Health Care
$0.6424as of 10/16/2026
Price chart
Active signals
CODX Signal Track Record
How signals performed across all stocks →What CODX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 19 | -24.1% | 21% | October 5, 2026 |
| Bollinger Band Breakdown | 18 | -15.7% | 17% | September 16, 2026 |
| Bollinger Band Breakout | 19 | -11.0% | 26% | May 7, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -4.8% | 30% | December 1, 2025 |
| Any 20-session window (baseline) | -6.8% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic test…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 115
- Website
- codiagnostics.com/
Fundamentals
- 1-day range
- $0.63$0.7499
- Market cap
- $9.91M
- P/E (trailing)
- —
- P/E (forward)
- -0.79
- EPS (trailing)
- $-23.84
- Dividend yield
- —
- Beta
- 3.14
- Avg. volume
- 363.1K
How Co-Diagnostics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Co-Diagnostics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CODXCo-Diagnostics Inc. Common Stock$0.654▼ 8.53%Market cap $9.91MP/E —$0.746$46.5
- SINTSiNtx Technologies Inc. Common Stock$1.74▼ 1.69%Market cap $10.36MP/E —$1.4$4.5
- ICCMIceCure Medical Ltd. Ordinary Shares$1.06▲ 1.92%Market cap $10.55MP/E —$1.04$29.46
- FEMYFemasys Inc. Common Stock$1.65▼ 4.90%Market cap $8.91MP/E —$1.67$22.2
- MODDModular Medical Inc. Common Stock$2.32▲ 7.18%Market cap $10.99MP/E —$1.72$18.76
- AMIXAutonomix Medical Inc. Common Stock$2.85▼ 2.90%Market cap $11.82MP/E —$2.44$32.55
- ICUSeaStar Medical Holding Corporation Common Stock$2.9▼ 5.23%Market cap $12.19MP/E —$2.07$7.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CODX Co-Diagnostics Inc. Common Stock | $9.91M | — | $0.654 | ▼ 8.53% | $0.746$46.5 |
| SINT SiNtx Technologies Inc. Common Stock | $10.36M | — | $1.74 | ▼ 1.69% | $1.4$4.5 |
| ICCM IceCure Medical Ltd. Ordinary Shares | $10.55M | — | $1.06 | ▲ 1.92% | $1.04$29.46 |
| FEMY Femasys Inc. Common Stock | $8.91M | — | $1.65 | ▼ 4.90% | $1.67$22.2 |
| MODD Modular Medical Inc. Common Stock | $10.99M | — | $2.32 | ▲ 7.18% | $1.72$18.76 |
| AMIX Autonomix Medical Inc. Common Stock | $11.82M | — | $2.85 | ▼ 2.90% | $2.44$32.55 |
| ICU SeaStar Medical Holding Corporation Common Stock | $12.19M | — | $2.9 | ▼ 5.23% | $2.07$7.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American TribeYahoo · 10/8/2026
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne DiseaseYahoo · 10/7/2026
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay DevelopmentYahoo · 10/6/2026
- Co-Diagnostics To Demonstrate Co-Dx PCR Platform, MTB Test At WHX LabsBenzinga · 10/6/2026
- Co-Diagnostics to Participate in Global Health Events During UN General Assembly WeekYahoo · 9/23/2026
- Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak InnovationYahoo · 9/21/2026
- Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026Yahoo · 9/17/2026
- Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Richard David Abbott · May 23, 2026 · Disposition680 @ $5.07
- James B. Nelson · May 23, 2026 · Grant1.7K
- Richard David Abbott · May 23, 2026 · Option Exercise1.9K
- Richard David Abbott · May 23, 2026 · Grant1.9K
- Brian Lee Brown · May 23, 2026 · Option Exercise3.8K
- Brian Lee Brown · May 23, 2026 · Disposition1.4K @ $5.07
- Brian Lee Brown · May 23, 2026 · Grant3.8K
- Eugene Durenard · May 23, 2026 · Option Exercise1.7K
- Eugene Durenard · May 23, 2026 · Grant1.7K
- Edward L. Murphy · May 23, 2026 · Option Exercise1.7K
- Edward L. Murphy · May 23, 2026 · Grant1.7K
- Dwight H. Egan · May 23, 2026 · Option Exercise4.6K
- Dwight H. Egan · May 23, 2026 · Disposition1.6K @ $5.07
- Dwight H. Egan · May 23, 2026 · Grant4.6K
- James B. Nelson · May 23, 2026 · Option Exercise1.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 49.2K
- Total value held
- $91.4K
- Institutional holders
- 12
- Unknown41.4K
- Unknown7.4K
- Unknown133
- Unknown88
- Unknown81
- Unknown58
- Unknown17
- Unknown17
- Unknown10
- Unknown7
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
CODX to Demo Co-Dx PCR Platform and MTB Test at WHX Labs
CODX announced it will show its Co-Dx PCR platform and a new MTB test at WHX Labs. The demo is part of the company’s push to broaden its diagnostic services. It may help the company move toward wider market use of its platform.
CODX to Demo Co-Dx PCR Platform and MTB Test at WHX Labs. CODX announced it will show its Co-Dx PCR platform and a new MTB test at WHX Labs. The demo is part of the company’s push to broaden its diagnostic services. It may help the company move toward wider market use of its platform.